# Ovarian Cancer

Itraconazole has intriguing retrospective-combination data in **recurrent ovarian clear cell carcinoma** and refractory ovarian cancer more broadly, but the evidence is still early and off-label.

### Overview

The main clinical interest here is itraconazole given with chemotherapy in difficult recurrent or refractory settings, where standard cytotoxic agents often have poor response rates.

### Key human data

* In a Japanese retrospective series of **nine patients** with recurrent ovarian clear cell carcinoma, itraconazole **400 mg daily** was given for **four days every two weeks** alongside docetaxel- and carboplatin-based chemotherapy.
* In that clear-cell cohort, the **response rate was 44%**. Median **progression-free survival was 544 days** and median **overall survival was 1,047 days**, which the authors considered promising for this hard-to-treat subtype.
* A separate retrospective series in **19 patients** with refractory ovarian cancer of mixed histologies compared chemotherapy with and without itraconazole.
* In that broader refractory group, median **progression-free survival was 103 vs 53 days** and median **overall survival was 642 vs 139 days** in favour of the itraconazole group.

### Practical interpretation

This is not definitive evidence. These were small, non-randomised, single-institution reports. Still, the size of the reported benefit in refractory settings is strong enough to keep ovarian cancer as one of the more important clinical-interest pages in the itraconazole topic.

Any use remains experimental and off-label, with the usual need to consider drug interactions, toxicity, and trial options first.

### References

Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma\
<https://pubmed.ncbi.nlm.nih.gov/24692739/>

Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer\
<https://pubmed.ncbi.nlm.nih.gov/24778064/>

Repurposing itraconazole as an anticancer agent\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC5529765/>

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent\
<https://ecancer.org/en/journal/article/521-repurposing-drugs-in-oncology-redo-itraconazole-as-an-anti-cancer-agent>

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/ovarian-cancer.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.